# Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

> **NCT03907527** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Precigen, Inc** · enrollment: 71 (estimated)

## Conditions studied

- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Ovarian Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Refractory Fallopian Tube Carcinoma
- Refractory Ovarian Carcinoma
- Refractory Primary Peritoneal Carcinoma
- Stage III Fallopian Tube Cancer AJCC V8
- Stage III Ovarian Cancer AJCC V8
- Stage III Primary Peritoneal Cancer AJCC V8
- Stage IIIA Fallopian Tube Cancer AJCC V8
- Stage IIIA Ovarian Cancer AJCC V8
- Stage IIIA Primary Peritoneal Cancer AJCC V8
- Stage IIIA1 Fallopian Tube Cancer AJCC V8
- Stage IIIA1 Ovarian Cancer AJCC V8
- Stage IIIA2 Fallopian Tube Cancer AJCC V8
- Stage IIIA2 Ovarian Cancer AJCC V8
- Stage IIIB Fallopian Tube Cancer AJCC V8
- Stage IIIB Ovarian Cancer AJCC V8
- Stage IIIB Primary Peritoneal Cancer AJCC V8
- Stage IIIC Fallopian Tube Cancer AJCC V8
- Stage IIIC Ovarian Cancer AJCC V8
- Stage IIIC Primary Peritoneal Cancer AJCC V8
- Stage IV Fallopian Tube Cancer AJCC V8
- Stage IV Ovarian Cancer AJCC V8
- Stage IV Primary Peritoneal Cancer AJCC V8
- Stage IVA Fallopian Tube Cancer AJCC V8
- Stage IVA Ovarian Cancer AJCC V8
- Stage IVA Primary Peritoneal Cancer AJCC V8
- Stage IVB Fallopian Tube Cancer AJCC V8
- Stage IVB Ovarian Cancer AJCC V8
- Stage IVB Primary Peritoneal Cancer AJCC V8

## Interventions

- **BIOLOGICAL:** PRGN-3005 UltraCAR-T cells
- **BIOLOGICAL:** PRGN-3005 UltraCAR-T cells

## Key facts

- **NCT ID:** NCT03907527
- **Lead sponsor:** Precigen, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-30
- **Primary completion:** 2024-12-15
- **Final completion:** 2028-11-15
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03907527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03907527, "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03907527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*